

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

**CHANGE OF BUILDING NAME OF HEAD OFFICE
AND
PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board of directors (the “**Board**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) hereby announces that the building name of the head office and principal place of business of the Company in Hong Kong will be changed from “Devon House” to “FWD Tower” with effect from 1 January 2026 (the “**Change of Building Name**”). Accordingly, the head office and principal place of business of the Company in Hong Kong will be updated with effect from 1 January 2026 as

Suites 2206–08, 22/F., FWD Tower, Taikoo Place, 979 King’s Road, Quarry Bay, Hong Kong

Save for the Change of Building Name, the physical location of the head office and principal place of business of the Company in Hong Kong remains unchanged.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 31 December 2025

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.

* For identification purpose only